Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration-Reference-Cited by-同舟云学术

Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration

Published:2017-09-02 Issue:1 Volume:17 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

Borne Ryan T.^ORCID,O’Donnell Colin,Turakhia Mintu P.,Varosy Paul D.,Jackevicius Cynthia A.,Marzec Lucas N.,Masoudi Frederick A.,Hess Paul L.,Maddox Thomas M.,Ho P. Michael

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12872-017-0671-6.pdf

Reference20 articles.

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.

2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857.

3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, TE RPAV, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139.

4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in patients with Atrial fibrillation. N Engl J Med. 2011;365(11):981.

5. Patel MR, Mahaffrey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial fibrillation. N Engl J Med. 2011;365(10):883.

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Oral Anticoagulant Adherence and Serious Clinical Outcomes in Patients With Atrial Fibrillation: A Long‐Term Retrospective Cohort Study;Journal of the American Heart Association;2024-09-09

2. Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States;Expert Review of Pharmacoeconomics & Outcomes Research;2024-09-03

3. Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis;Journal of Internal Medicine;2024-09-02

4. Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence;International Journal of Clinical Pharmacy;2024-08-27

5. Atrial fibrillation fact sheet in Korea 2024: part 2—stroke prevention in Korean patients with atrial fibrillation;International Journal of Arrhythmia;2024-08-01